AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1.-11. (Canceled)
- 12. (Currently Amended) A method to remove CD4⁺ CD25⁺ regulatory T cells from human blood comprising the steps of:
 - (a) contacting human blood comprising CD4⁺CD25⁺ regulatory T cells with ligands antibodies specifically binding to one or more members selected from the group consisting of:
 - (i) the CD4, CD25 and CTLA-4 entities on the T cells or
 - (ii) the CD25 and CTLA-4 entities on the T cells; and
 - (b) removing said CD4⁺CD25⁺ regulatory T cells from the human blood; and
 - (c) identifying the CD4⁺CD25⁺T regulatory cells from the human blood in step (b) as CD4⁺CD25⁺ regulatory T cells.
 - 13.-24. (Canceled)
- 25. (Previously Presented) The method of claim 12, whereby said CD4⁺ CD25⁺ regulatory T cells are removed from the human peripheral blood.
 - 26. (Previously Presented) The method of claim 12, wherein said method further

comprises utilizing immunoadsorption methods.

- 27. (Previously Presented) The method of claim 12, wherein said method further comprises utilizing a stimulating agent or antigen presenting cells.
- 28. (Currently Amended) The method of claim 12, wherein step (c) comprises the further comprising a step of testing the CD4⁺ CD25⁺ T cells for a regulatory property of CD4⁺ CD25⁺ T cells.
- 29. (Previously Presented) The method of claim 28, wherein said step of testing the CD4⁺ CD25⁺ T cells for a regulatory property of CD4⁺ CD25⁺ T cells comprises analyzing the CD4⁺ CD25⁺ T cells for a property selected from the group consisting of:
 - (a) constitutive expression of CTLA-4;
 - (b) being non-proliferative following stimulation via the T cell receptor;
 - (c) being in an anergic state;
 - (d) being in an anergic state that is partially reversed by IL-15;
 - (e) being in an anergic state that is partially reversed by IL-2 and IL-15;
 - (f) releasing IL-10 following stimulation with allogeneic mature dendritic cells;
 - (g) releasing IL-10 following stimulation with anti-CD28 antibodies and immobilized anti-CD3 antibodies;
 - (h) suppressing the activation and proliferation of CD4+ T cells in a coculture experiment;
 - (i) suppressing the activation and proliferation of CD8⁺ T cells in a coculture

experiment; and

- (j) having a cytokine profile that differs from that of CD4⁺CD25⁻ T cells.
- 30. (Previously Presented) The method of claim 29, wherein said step of testing the CD4⁺ CD25⁺ T cells for a regulatory property of CD4⁺ CD25⁺ T cells comprises the step of analyzing the CD4⁺ CD25⁺ T cells for the property of suppressing the activation and proliferation of CD4⁺ T cells in a coculture experiment, wherein said analyzing comprises determining whether said property of suppressing the activation and proliferation of CD4⁺ T cells is contact-dependent.
- 31. (Previously Presented) The method of claim 29, wherein said step of testing the CD4⁺CD25⁺ T cells for a regulatory property of CD4⁺CD25⁺ T cells comprises the step of analyzing the CD4⁺CD25⁺ T cells for the property of suppressing the activation and proliferation of CD4⁺ T cells in a coculture experiment, wherein said analyzing comprises the use of CD4⁺ CD25⁺ T cells that have been activated and fixed.
- 32. (Previously Presented) The method of claim 29, wherein said step of testing the CD4⁺CD25⁺ T cells for a regulatory property of CD4⁺CD25⁺ T cells comprises the step of analyzing the CD4⁺CD25⁺ T cells for a cytokine profile of predominant secretion of IL-10 and only low levels of secretion of IL-2, IL-4, and IFN-γ.
- 33. (Currently Amended) A method to remove CD4⁺ CD25⁺ regulatory T cells from human blood comprising the steps of:
 - (a) isolating a population of CD4⁺ T cells from the blood;

- (b) isolating a population of CD4⁺ CD25⁺ T cells from the population of CD4⁺ T cells isolated in step (a); and
- (c) <u>identifying testing the CD4⁺ CD25⁺ T cells isolated in step (b) for constitutive expression of CTLA-4 as CD4⁺ CD25⁺ regulatory T cells.</u>